Arimidex Observational: Reason for and Effect of Change From Tamoxifen

The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Research Site, 's-Hertogenbosch, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Postmenopausal
Hormone sensitive breast cancer
Patient uses tamoxifen or has stopped taking tamoxifen less than 7 days ago

Exclusion criteria

Visceral metastases
Patients with signs of progression at the moment of changing therapy
Patients who have used other endocrine treatments for breast cancer besides tamoxifen

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Arimidex: Reason for and Effect of Change From Tamoxifen

Acronym: ARREST

Important dates

Study start: 2004
First posted: Nov 1, 2005
Registry last updated: Oct 12, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed